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Aim To immunohistochemically evaluate the expression 
of  MAGE-A1,  MAGE-A,  and  NY-ESO-1  cancer/testis  (C/T) 
tumor antigens in medullary breast cancer (MBC) tumor 
samples and to analyze it in relation to the clinicopatho-
logical features.
Methods This retrospective study included samples from 
49 patients: 40 with typical MBC and 9 with atypical MBC. 
Tumor specimens were obtained from patients operated 
on in the University Hospital for Tumors and the Sisters of 
Mercy University Hospital, Zagreb, Croatia, from 1999 to 
2005. Standard immunohistochemistry was used on archi-
val paraffin-embedded MBC tissues.
Results MAGE-A1, MAGE-A, and NY-ESO-1 antigens were 
expressed in 33% (16/49), 33% (16/49), and 22% (11/49) of 
patients, respectively. No difference between the groups 
with and without C/T tumor antigen expression in age at 
diagnosis, tumor size, axillary lymph node metastasis, adju-
vant therapy, and HER-2 expression was identified. Signifi-
cantly more patients died in the MAGE-A-positive group 
than in the MAGE-A-negative group (P = 0.010), whereas 
a borderline significance was found between MAGE-A1-
positive and the MAGE-A1-negative group (P = 0.079) and 
between NY-ESO-1-positive and NY-ESO-1-negative group 
(P = 0.117).  Overall  survival,  as  evaluated  by  the  Kaplan-
Meier curves, was lower in MAGE-A1- (P = 0.031), MAGE-A- 
(P = 0.004), NY-ESO-1-positive groups (P = 0.077).
Conclusion Expression of C/T antigens may represent a 
marker of potential prognostic relevance in MBC. Received: November 22, 2010
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Breast cancers are a very heterogeneous group of diseases 
in terms of natural history, histopathological features, ge-
netic alterations, gene-expression profiles, and response 
to treatment (1-5). Medullary breast cancers (MBC), both 
typical and atypical, account for <2% of breast invasive 
carcinomas. Despite histopathologically highly malignant 
characteristics, operable and non-metastatic MBCs have 
a more favorable prognosis than the more common infil-
trating ductal breast carcinoma of the same stage (1,6-13). 
Recent updating of breast cancer classification, based on 
gene expression profile analyses, has indicated that MBCs 
can be considered as part of the basal-like carcinoma spec-
trum made up of the estrogen receptor (ER) negative-, pro-
gesterone receptor (PR) negative-, and human epidermal 
growth factor receptor 2 (HER-2)-negative tumors (“triple-
negative phenotype”) (14-17).
Cancer/testis (C/T) antigens are a subgroup of tumor-as-
sociated  antigens  expressed  in  normal  testis  germ  line 
cells and trophoblast, and in various malignancies of dif-
ferent histological types. They were discovered in the last 
two decades by a combination of immunological and mo-
lecular biology techniques. Most genes that encode these 
antigens are localized on the X-chromosome, frequently 
as multigene families and are referred to as CT-X genes or 
CT-X antigens (18-23). Biological functions of C/T genes 
and C/T antigens in both germ lines and tumors remain 
poorly understood. Due to their tumor-associated expres-
sion pattern and limited presence in normal tissues, C/T 
antigens appear to be valuable targets for immunothera-
py of cancer. The best-studied C/T antigens are those of 
the MAGE-A family and the NY-ESO-1 antigen (18-23). Our 
initial reports on C/T antigens expression detected by im-
munohistochemistry in breast invasive ductal carcinomas 
of no special type (24,25) has been confirmed by other 
studies (26,27). However, these studies have not been per-
formed on special or relatively rare histological types of 
breast cancers, such as the MBC.
We  have  recently  reported  clinicopathological  features 
of MBCs in 48 patients who were operated on in our two 
hospitals between 1999 and 2005 (28). The present study 
includes immunohistochemical analysis of the expression 
of C/T antigens MAGE-A, MAGE-A1, and NY-ESO 1 in these 
MBC samples.
PAtIeNtS ANd MethodS
This retrospective study included samples from 49 pa-
tients: 40 with typical and 9 with atypical MBC (28). 
Tumor specimens were obtained from patients operated 
on in the University Hospital for Tumors and the Sisters of 
Mercy University Hospital, Zagreb, Croatia, from 1999 to 
2005. The patients were identified retrospectively in 2006 
tABle 1. Patients’ and medullary breast cancer characteristics
Characteristics, No. (%)
Medullary 
breast cancer 
patients (n = 49)
Age at diagnosis (years; median, range) 51 (28-82)
type of surgery:
mastectomy with axillary dissection 29 (59)
segmentectomy with axillary dissection 20 (41)
Tumor size (cm; median, range)   2.4 (0.8-5.0)
pT1 20 (41)
pT2 28 (57)
pT3   1 (2)
pT4  0
Axillary lymph node metastasis
no 32 (65)
yes 17 (35)
Adjuvant therapy*:
no   2 (4)
radiotherapy 12 (24)
chemotherapy 23 (47)
chemotherapy + radiotherapy 12 (24)
Survival (follow-up time in months; median, 
range):
68 (8-164)
alive 43 (88)
dead   6 (12)
dead (follow-up time in months; median, range) 42.5 (13-53)
estrogen receptor:
negative 46 (94)
positive   3 (6)
Progesterone receptor:
negative 41 (84)
positive   8 (16)
human epidermal growth factor receptor 2:
negative (-, + or ++) 35 (71)
positive (+++) 14 (29)
MAGe-A1:
negative (-) 33 (67)
positive (+,++,+++) 16 (33)
MAGe-A:
negative (-) 33 (67)
positive (+,++,+++) 16 (33)
NY-eSo 1:
negative (-) 38 (78)
positive (+,++,+++) 11 (22)
*At that time, adjuvant trastuzumab was not a standard therapy for 
the heR-2 +++ positive patients, ie, a therapy covered by our national 
health insurance system.173 Matković et al: Expression of MAGE-A and NY-ESO-1 in medullary breast cancer
www.cmj.hr
from pathological reports from the Departments of Pathol-
ogy of the two hospitals. At the time of diagnosis, patients 
had nonmetastatic MBC (M0). Adjuvant therapy data were 
obtained from patients’ medical reports from the hospi-
tals’ Oncology Departments (Table 1). The patients’ survival 
data were obtained at the end of 2008 from the Croatian 
National Cancer Registry and through personal contacts 
with patients and their physicians. The data on the disease-
free survival were not available. The study protocol was ap-
proved by the Ethics Committee of the hospitals (28).
For routine histological analysis, the resected breast tissue 
was fixed immediately after surgery in 10% buffered for-
malin and later embedded in paraffin. From paraffin-em-
bedded tumor samples, 4-μm thick sections were cut and 
stained with hematoxylin and eosin, and reviewed by the 
experienced pathologist (VS, BK, IN) in order to establish 
the  diagnosis.  Immunohistochemical  staining  was  per-
formed by appropriate monoclonal antibodies (mab) in ac-
cordance with the manufacturer’s instructions, as previous-
ly reported (19,24,25,28). Mab 1D5 (M7047, Dako, Glostrup, 
Denmark) and 1A6 (M3569 Dako) were used to detect ER 
and PR receptors, respectively. The DAKO Hercept TestTM 
kit (polyclonal antibody DA485, K5206, Dako), approved 
by the Food and Drug Administration, was used to detect 
HER-2. Immunohistochemical staining was performed fol-
lowing  the  Microwave  Streptavidin  Immuno  Peroxidase 
protocol on DAKO TechMate Horizon automated immu-
nostainer. Immunohistochemistry for C/T antigens MAGE-
A1 (mab 77B) (29), multi MAGE-A (mab 57B) (30), and NY-
ESO-1 (mab B9.8.1) (31) was performed following the same 
procedure.  Positive  staining  for  ER  and  PR  was  defined 
as nuclear staining in ≥10% of tumor cells, while positive 
staining for HER-2 was defined based on the percentage of 
tumor cells and the intensity of membrane staining. HER-2 
immunostaning  was  considered  positive  when  strong 
(+++) membranous staining was observed in at least 10% 
of tumor cells, whereas cases with 0 to ++ were regard-
ed as negative (19,28). The staining for MAGE-A1, MAGE-A, 
and NY-ESO-1 was defined as weak with positive reaction 
when there were ≤10% of tumor cells (+), moderate with 
positive reaction when there were between 10 and 50% of 
tumor cells (++), and strong with positive reaction (+++) 
when there were >50% of tumor cells (Table 1) (24,25,28). 
Representative examples of immunohistochemical stain-
ing obtained with these mabs are presented in Figure 1.
Statistical analysis was performed using Statistics 5.5 soft-
ware package (StatSoft, Inc., Tulsa, OK, USA). χ2 test was 
used for the group difference analysis of qualitative fea-
tures, Fischer exact test for variables with low frequencies, 
nonparametric Mann-Whitney U test for numeric variables, 
and  Kaplan-Meier  curves  with  log-rank  test  for  survival 
analysis. P values <0.05 were considered significant.
ReSultS ANd dISCuSSIoN
Patients’  median  age  was  51  years  (range,  28-82  years). 
Modified radical mastectomy was the predominant opera-
tional procedure (29/49; 59%). The median tumor size was 
2.4 cm (range, 0.8-5.0 cm) and axillary lymph node metas-
tases were found in 17 out of 49 patients (35%). pT1 tumor 
tABle 2. Comparison of groups with and without MAGe-A1, MAGe-A, and NY-eSo-1 expression according to medullary breast cancer 
clinicopathological features
No. (%) of patients with tumor expressing
MAGe-A1 MAGe-A NY-eSo-1
Characteristics
negative 
n = 33 (67)
positive 
n = 16 (33) P
negative 
n = 33 (67)
positive 
n = 16 (33) P
negative 
n = 38 (78)
positive 
n = 11 (22) P
Age (years; median, range) 52 (28-69) 48.5 (32-82) 0.847‡ 53 (28-69) 47.5 (32-82) 0.423‡ 52 (34-82) 49 (28-61) 0.110‡
Tumor size (cm; median, range)   2.4 (0.8-5.0)  2.3 (0.8-4.0) 0.659‡   2.3 (0.8-5.0)  2.5 (1.2-4.0) 0.165‡   2.3 (0.8-5.0)   2.5 (1.1-4.0) 0.499‡
Axillary lymph node metastasis 12 (36)   5 (31) 0.973* 13 (39)   4 (25) 0.501* 15 (40)   2 (18) 0.287†
Adjuvant chemotherapy 22 (67) 13 (81) 0.336† 25 (76) 10 (63) 0.501† 28 (74)   7 (64) 0.705†
Adjuvant radiotherapy 15 (46)   9 (56) 0.686* 18 (55)   6 (38) 0.415* 19 (50)   5 (46) 0.938*
Estrogen receptor positive   2 (6)   1 (6) -   3 (9)   0 (0) -   3 (8)   0 (0) -
Progesterone receptor positive   7 (21)   1 (6) 0.245†   7 (21)   1 (6) 0.245†   7 (18)   1 (9) 0.663†
Human epidermal growth factor 
receptor 2 positive (+++)
  9 (27)   5 (31) 1.000†   7 (21)   7 (44) 0.175† 11 (29)   3 (27) 1.000†
No. of dead patients   2 (6)   4 (25) 0.079†   1 (3)   5 (31) 0.010†   3 (8)   3 (27) 0.117†
*χ2 test.
†Fischer exact test.
‡Mann-Whitney u test; significant values are italicized.CLINICAL SCIENCES 174 Croat Med J. 2011; 52: 171-7
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size was found in 20, pT2 in 28, and pT3 in 1 patient. The 
majority of patients were ER- and PR-negative (94% and 
84%, respectively). Twenty nine percent of patients (14 out 
of 49) were HER-2 antigen strongly positive (+++). Adju-
vant therapy was applied in all but 2 patients (4%). The 
mean follow-up time of patients was 68 months (range, 8 
to 164 months) and 43 out of 49 patients survived (88%). 
MAGE-A1,  multi  MAGE-A,  and  NY-ESO-1  specific  stain-
ing was detectable in 33% (16/49), 33% (16/49), and 22% 
(11/49) of patients, respectively (Table 1).
Groups with and without expression of MAGE-A1, multi 
MAGE-A, and NY-ESO-1 were compared according to the 
following MBC clinicopathological features: patient’s age at 
diagnosis, type of operation, tumor size, presence of axillary 
lymph node metastasis, adjuvant therapy (chemotherapy 
and radiotherapy), HER-2 expression, and patient’s survival. 
There was no difference between groups with and without 
C/T tumor antigen expression in these clinicopathologic 
parameters. Compared with MAGE-A-negative group, sig-
nificantly greater number of patients died in the MAGE-A-
positive group (P = 0.010), whereas borderline significance 
Figure 1.
Immunohistochemical staining of MAGe-A1 and MAGe-A in medullary 
breast cancer tissues. (A) MAGe-A1 positive staining by monoclonal an-
tibody 77B (PAP 40 × ). (B) MAGe-A positive staining by monoclonal an-
tibody 57B (PAP 200 × ).
Figure 2.
Kaplan-Meier survival curves of the expression of MAGe-A1, log rank 
test; P = 0.031 (A), MAGe-A, log rank test; P = 0.004 (B), and NY-eSo-1, log 
rank test; P = 0.077 (C) in medullary breast cancer tissues. Closed circle – 
dead patients; open circle – alive patients; full line – negative expression; 
interrupted line – positive expression.175 Matković et al: Expression of MAGE-A and NY-ESO-1 in medullary breast cancer
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was found between the MAGE-A1-positive and MAGE-A1- 
negative group (P = 0.079) and betweenNY-ESO-1-positive 
and NY-ESO-1-negative group (P = 0.117). Overall survival 
of patients with MBC, as evaluated by the Kaplan-Meier 
curves, was lower in the groups expressing C/T antigens 
(Table 2). In particular, MAGE-A1-positive group had a sig-
nificantly  lower  overall  survival  (P = 0.031,  log-rank  test) 
than MAGE-A1-negative group (Figure 2A). Similarly, multi 
MAGE-A positivity was also associated with a significantly 
lower overall survival (P = 0.004) (Figure 2B). A similar trend 
was also detectable for NY-ESO-1 (P = 0.077), although the 
difference did not reach significance (Figure 2C).
Our study suggested that the studied C/T antigens may 
be used in MBC as tumor markers of potential prognostic 
relevance. Due to the relative rarity of this type of breast 
cancer, in order to obtain a final confirmation of this obser-
vation, the expression of these C/T antigens needs to be in-
vestigated on a greater number of tumor samples. Interest-
ingly, however, a recent publications by Grigoriadis et al (27) 
and Curigliano et al (32) have pointed out that the expres-
sion of CT-X antigens is more frequent in the ER-negative 
subgroup of breast cancers, including triple-negative and 
basal-like breast cancers. However, expression of CT-X anti-
gens, to our knowledge, has not been studied specifically in 
MBC. In studies on squamous non-small-cell lung carcino-
mas (33), transitional cell carcinomas of the urinary bladder 
(34), and gynecologic (35,36) and gastric neoplasms (37), 
expression of C/T antigens has been found to be correlated 
with patients’ shorter tumor-specific survival.
It is still unclear whether C/T antigen expression contrib-
utes to tumorigenesis or represents an epiphenomenon in 
the process of cellular transformation related to the global 
genome hypomethylation (20-22,38-41) frequently occur-
ring in highly aggressive cancers. However, our data rein-
force the notion that C/T antigen specific immunization, 
possibly in the early stages of the disease, ie, after surgery, 
might be clinically relevant in selected groups of patients 
(19,20,23).
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